DOCK8 gene mutation patients with SLE respond to immunosuppressive therapy, but 10‐year follow‐up of a DOCK8‐deficient child with SLE feature reveals more effective therapies are needed.85 This evidence concerns the gene DOCK8 and systemic lupus erythematosus.